Genelux Common Stock Alpha and Beta Analysis
| GNLX Stock | 2.69 0.20 8.03% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Genelux Common. It also helps investors analyze the systematic and unsystematic risks associated with investing in Genelux Common over a specified time horizon. Remember, high Genelux Common's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Genelux Common's market risk premium analysis include:
Beta (2.08) | Alpha 0.85 | Risk 6.66 | Sharpe Ratio 0.0934 | Expected Return 0.62 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Genelux |
Genelux Common Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Genelux Common market risk premium is the additional return an investor will receive from holding Genelux Common long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Genelux Common. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Genelux Common's performance over market.| α | 0.85 | β | -2.08 |
Genelux Common expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Genelux Common's Buy-and-hold return. Our buy-and-hold chart shows how Genelux Common performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Genelux Common Market Price Analysis
Market price analysis indicators help investors to evaluate how Genelux Common stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Genelux Common shares will generate the highest return on investment. By understating and applying Genelux Common stock market price indicators, traders can identify Genelux Common position entry and exit signals to maximize returns.
Genelux Common Return and Market Media
The median price of Genelux Common for the period between Sun, Sep 1, 2024 and Sat, Nov 30, 2024 is 2.55 with a coefficient of variation of 12.81. The daily time series for the period is distributed with a sample standard deviation of 0.33, arithmetic mean of 2.59, and mean deviation of 0.26. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 23383 shares by Szalay Aladar of Genelux Common at 2.7028 subject to Rule 16b-3 | 09/09/2024 |
2 | Disposition of 20384 shares by Szalay Aladar of Genelux Common at 2.5109 subject to Rule 16b-3 | 09/10/2024 |
3 | Disposition of 31376 shares by Szalay Aladar of Genelux Common at 2.6207 subject to Rule 16b-3 | 09/11/2024 |
4 | Disposition of 31777 shares by Szalay Aladar of Genelux Common at 2.7294 subject to Rule 16b-3 | 09/12/2024 |
5 | Disposition of 33080 shares by Szalay Aladar of Genelux Common at 2.5679 subject to Rule 16b-3 | 09/13/2024 |
6 | Acquisition by Joseph Cappello of 11557 shares of Genelux Common subject to Rule 16b-3 | 09/24/2024 |
7 | Disposition of 5200 shares by Yong Yu of Genelux Common at 19.106 subject to Rule 16b-3 | 10/01/2024 |
8 | Acquisition by Thomas John of 2500 shares of Genelux Common at 5.25 subject to Rule 16b-3 | 10/02/2024 |
9 | Acquisition by Scigalla Paul of 16666 shares of Genelux Common at 6.0 subject to Rule 16b-3 | 10/18/2024 |
10 | Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer | 10/22/2024 |
11 | While institutions invested in Genelux Corporation benefited from last weeks 34 percent gain, individual investors stood to gain the most | 10/31/2024 |
12 | Genelux GAAP EPS of -0.19 beats by 0.01 | 11/15/2024 |
13 | Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors | 11/19/2024 |
About Genelux Common Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Genelux or other stocks. Alpha measures the amount that position in Genelux Common has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Interest Debt Per Share | 0.19 | 0.18 | Revenue Per Share | 0.006959 | 0.006611 |
Genelux Common Upcoming Company Events
As portrayed in its financial statements, the presentation of Genelux Common's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Genelux Common's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Genelux Common's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Genelux Common. Please utilize our Beneish M Score to check the likelihood of Genelux Common's management manipulating its earnings.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Genelux Common
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Genelux Stock Analysis
When running Genelux Common's price analysis, check to measure Genelux Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genelux Common is operating at the current time. Most of Genelux Common's value examination focuses on studying past and present price action to predict the probability of Genelux Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genelux Common's price. Additionally, you may evaluate how the addition of Genelux Common to your portfolios can decrease your overall portfolio volatility.